Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab plus standard-of-care versus standard-of-care alone in advanced HER2-positive biliary tract cancer
jRCT2031240223Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, open-label trial in biliary cancer comparing Zanidatamab plus standard-of-care with Standard-of-care alone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2024; status: recruiting.
02
Drugs
zanidatamab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCT2031240223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240223.